Scientists from Skoltech and the University of Potsdam have developed a physical theory that sheds light on how molecular ...

PBGENE-HBV is Precision's wholly owned in vivo gene editing program under investigation in a global first-in-human clinical trial, which is designed to be a potentially curative treatment for chronic ...

Idvynso uniquely offers a two-drug, tenofovir-free, non-INSTI single-tablet regimen intended for switch in stable, suppressed ...

Acurx Pharmaceuticals, Inc. ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today ...

PBGENE-HBV is the only clinical stage program targeting the elimination of cccDNA leading to sustained loss of HBV DNA. The FDA has previously provided guidance thatsustained loss of HBV DNA is an ...

Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven ...

Aligos to receive an upfront payment of $25M USDUp to $420M USD in clinical, regulatory, and sales milestones along with tiered, high ...

NAD levels naturally decline with age, so NMN supplementation has been marketed as a way to restore NAD levels, sometimes with anti-aging claims, Jafari said. But raising NAD+ in blood (a biomarker) ...

This approval marks an important new chapter in Merck’s long-standing commitment to research and discovery for people living ...

Explore 25 Historic Mysteries Scientists Are Still Unraveling, from vanished cities to lost treasures. Dive into ancient ...

The U.S. Food and Drug Administration has granted Priority Review for Aicuris’ New Drug Application for pritelivir, a novel helicase primase inhibitor developed to treat refractory herpes simplex ...